REGN

Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026 | Benchmark More Than 1,800 Biopharma Deals with Various Indexes

GlobeNewswire Inc. · 18h ago

Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider

GlobeNewswire Inc. · 2d ago

Dupilumab Achieves Record $11.9 Billion in Global Sales Amidst Continued Growth

GlobeNewswire Inc. · 14d ago

Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.

The Motley Fool · 15d ago

Questex’s PODD, the Premier Gathering for Drug Delivery Industry Leaders, Announces the 16th Annual Conference Agenda

GlobeNewswire Inc. · 24d ago

AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King?

The Motley Fool · 25d ago

Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?

The Motley Fool · 27d ago

This Stock Is Up 58% This Year. Is It too Late to Buy?

The Motley Fool · 30d ago

Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?

The Motley Fool · 32d ago

Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Benzinga · 36d ago

Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsight

GlobeNewswire Inc. · 37d ago

Parabilis Medicines Announces Pricing of Upsized Initial Public Offering

Benzinga · 38d ago

Treg Cell-Based Therapies Clinical Trial Pipeline Appears Robust With 29+ Key Pharma Companies Actively Working in the Domain | DelveInsight

GlobeNewswire Inc. · 38d ago

CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

GlobeNewswire Inc. · 44d ago

Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight

GlobeNewswire Inc. · 45d ago

Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak

GlobeNewswire Inc. · 50d ago

Investment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing

The Motley Fool · 52d ago

CytomX Therapeutics to Present at Upcoming June Investor Conferences

GlobeNewswire Inc. · 57d ago

Nvidia Earnings Could Decide Whether the AI Trade Still Holds

Investing.com · 60d ago

Myasthenia Gravis Market Set to Surpass USD 16 Billion by 2036, Fueled by Rising Diagnosed Prevalence and Wave of Targeted Biologic Approvals | DelveInsight

GlobeNewswire Inc. · 60d ago

Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas

GlobeNewswire Inc. · 60d ago

Why Is Regeneron Stock Sinking Monday?

Benzinga · 60d ago

Stock Market Today: Dow Jones, S&P 500 Futures Drop Following Drone Strike On UAE Nuclear Plant—Regeneron Pharma, NextNRG, ServiceNow In Focus

Benzinga · 60d ago

Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma

GlobeNewswire Inc. · 63d ago

UPDATE – Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair

GlobeNewswire Inc. · 63d ago